Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06120777 · ClinicalTrials.gov registry record · NA

Clinical Validation for SpO2 Function of Masimo INVSENSOR00069

A NA study, sponsored by Masimo Corporation.

Completed
Registry status
NA
Development phase
89
Enrollment target

NCT06120777: Completed NA study, sponsored by Masimo Corporation.

NCT06120777 is a NA study that has completed, run by Masimo Corporation. The registered enrollment target is 89 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06120777, a NA study, has completed, sponsored by Masimo Corporation.

COMPLETED
Registry status
NA
Development phase
89 participants
Enrollment target

Study Summary

Assess the accuracy of INVSENSOR00069's peripheral oxygen saturation (SpO2) against contemporaneous measurement from arterial blood gas (ABG) analysis.

Primary Outcome

The SpO2 accuracy of Masimo INVSENSOR00069 was determined by calculating the accuracy root mean-squared (Arms) difference between the measured values (SpO2) to the reference values (SaO2) in accordance with ISO-80601-2-61. Arms= √(∑(i=1 to n) ((SpO2\_i-SaO2\_i )\^2 ))/n.

Interventions

  • DEVICE INVSENSOR00069

Trial Details

FieldValue
Enrollment Target 89 participants
Start Date 2023-11-01
Est. Completion 2023-12-12
Phase NA
Masimo Corporation

96 total trials

What the finished NCT06120777 record still lists

NCT06120777 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 89 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).

The record links to 0 conditions, and to 1 intervention - of which INVSENSOR00069 is the first listed.

NCT06120777 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT06120777 about?

NCT06120777 is a clinical study titled "Clinical Validation for SpO2 Function of Masimo INVSENSOR00069". Assess the accuracy of INVSENSOR00069's peripheral oxygen saturation (SpO2) against contemporaneous measurement from arterial blood gas (ABG) analysis.

What is the current status of trial NCT06120777?

This trial is currently completed. It is a NA study. The enrollment target is 89 participants. The study started on 2023-11-01. Estimated completion is 2023-12-12.

What interventions are being tested in trial NCT06120777?

The interventions under investigation include: INVSENSOR00069 (DEVICE).

Who is sponsoring clinical trial NCT06120777?

This trial is sponsored by Masimo Corporation, which has 96 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT06120777's enrollment target sits among peer trials

89 972nd of 2000 higher than 1,029 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03682289 · 89 participants · Phase 2

    Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

  • NCT04787939 · 89 participants · NA

    Early Feeding After Oral Cavity Reconstruction

  • NCT05480449 · 89 participants · Phase 1

    Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)

  • NCT05604131 · 89 participants · Phase 2

    Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06120777, the US trial registry maintained by the National Library of Medicine. NCT06120777 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.